Using an agnostic nanoparticle-based strategy, we first discovered that the silencing of both CCR1 and CCR5 was necessary and sufficient to change the phenotype and function of tumor-infiltrating myeloid cells and restrain tumor progression in all mouse cancer types tested. This evidence concerns the gene CCR5 and cancer.